{"schema_version":"secwatch.filing_event.v1","accession":"0001021771-22-000060","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.901697+00:00","generated_at":"2026-06-22T01:10:00.584540+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"BioRestorative shareholders approve all proposals, including reincorporation to Nevada","bullets":["Elected David Rosa and Francisco Silva as Class II directors; 1.8M and 1.95M shares for, respectively.","Approved amendments to 2021 Stock Incentive Plan: 1.79M for, 163K against.","Authorized reincorporation from Delaware to Nevada: 1.95M for, 12K against.","Non-binding advisory vote approved executive compensation; future vote recommended every three years.","Ratified Marcum LLP as independent auditor for FY2022: 2.64M for, 16K against."],"urls":{"canonical":"https://secwatch.observer/filing/0001021771-22-000060","json":"https://secwatch.observer/filing/0001021771-22-000060.json","markdown":"https://secwatch.observer/filing/0001021771-22-000060.md","text":"https://secwatch.observer/filing/0001021771-22-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/form8kdtd11322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:10:00.584540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04dd6e0c91700194b32bf7d66546da2adfa0d1f4","claim":"BioRestorative Therapies, Inc. shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-11-03 meeting.","evidence_excerpt":"6. Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For 2,636,553 Against 15,926 Abstentions 3,530","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"265bb77be6d3456a5c35f6c533eef12111325aba","claim":"BioRestorative Therapies, Inc. shareholders approved Election of Class II Directors at the 2022-11-03 meeting.","evidence_excerpt":"1. Election of Class II Directors: Number of Shares For Withheld Broker Non-Votes David Rosa 1,812,382 159,781 683,846 Francisco Silva 1,951,117 21,046 683,846","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"2e5f32ab730b205c8808a6960e33c6f75eaff4ef","claim":"BioRestorative Therapies, Inc. shareholders approved Recommendation, on a non-binding advisory basis, as to frequency of future advisory votes on the Company’s executive compensation at the 2022-11-03 meeting.","evidence_excerpt":"5. Recommendation, on a non-binding advisory basis, as to frequency of future advisory votes on the Company’s executive compensation: Three Years 1,768,754 Two Years 18,440 One Year 171,693 Abstentions 13,276","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"5135468caec341555e83756665edecd8f86b4456","claim":"BioRestorative Therapies, Inc. shareholders approved Approval of amendments to the Company’s 2021 Stock Incentive Plan at the 2022-11-03 meeting.","evidence_excerpt":"2. Approval of amendments to the Company’s 2021 Stock Incentive Plan: For 1,790,399 Against 163,058 Abstentions 18,706 Broker Non-Votes 683,846","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"bbe8ed51ec4449a2242fd73db1eea50bfe818812","claim":"BioRestorative Therapies, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers at the 2022-11-03 meeting.","evidence_excerpt":"4. Approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers: For 1,785,569 Against 169,088 Abstentions 17,506 Broker Non-Votes 683,846","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-03"}],"fact_type":"shareholder_vote"},{"claim_id":"d31e392b5be5b4aba690df7fd7a45d738d7c10ec","claim":"BioRestorative Therapies, Inc. shareholders approved Authorization of the reincorporation of the Company from the State of Delaware to the State of Nevada at the 2022-11-03 meeting.","evidence_excerpt":"3. Authorization of the reincorporation of the Company from the State of Delaware to the State of Nevada: For 1,954,622 Against 12,382 Abstentions 5,159 Broker Non-Votes 683,846","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177122000060/0001021771-22-000060-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}